Robert LeBoyer
Stock Analyst at Noble Financial
(0.05)
# 4,378
Out of 4,402 analysts
407
Total ratings
28.4%
Success rate
-10.6%
Average return
Main Sectors:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals | Reiterated: Buy | $10 | $3.57 | +180.11% | 20 | Jun 10, 2026 | |
| GLSI Greenwich LifeSciences | Reiterated: Buy | $45 | $23.03 | +95.40% | 9 | Jun 2, 2026 | |
| MAIA MAIA Biotechnology | Reiterated: Buy | $14 | $1.30 | +976.92% | 21 | Jun 2, 2026 | |
| GOVX GeoVax Labs | Reiterated: Buy | $10 | $1.18 | +747.46% | 25 | May 27, 2026 | |
| COCP Cocrystal Pharma | Reiterated: Buy | $6 → $10 | $1.01 | +890.10% | 28 | May 27, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | $12 | $1.59 | +654.72% | 5 | May 22, 2026 | |
| UNCY Unicycive Therapeutics | Reiterated: Buy | $60 | $7.69 | +680.23% | 18 | May 13, 2026 | |
| GYRE Gyre Therapeutics | Reiterated: Buy | $20 | $6.05 | +230.58% | 10 | May 8, 2026 | |
| TOI The Oncology Institute | Reiterated: Buy | $8 | $5.13 | +55.95% | 7 | May 8, 2026 | |
| OCGN Ocugen | Reiterated: Buy | $12 | $1.22 | +883.61% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $4.03 | +1,016.63% | 15 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.52 | +326.14% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $0.739 | +1,117.86% | 5 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $37 | $10.65 | +247.42% | 30 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0983 | - | 5 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.27 | n/a | 24 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.12 | n/a | 36 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1749 | n/a | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.07 | n/a | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.6536 | n/a | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $9 | $1.28 | n/a | 11 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $0.71 | $0.093 | n/a | 2 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $20 | $2.50 | n/a | 10 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $27 | $0.0001 | n/a | 7 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $15 | $3.80 | n/a | 8 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $5.42 | n/a | 1 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $14 | $1.25 | n/a | 7 | Jan 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.72 | n/a | 2 | Dec 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $1.10 | n/a | 6 | Dec 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.0001 | n/a | 5 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.05 | n/a | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.82 | n/a | 8 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $2.01 | n/a | 1 | Feb 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.25 | n/a | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.57 | n/a | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $17 → $1 | $31.74 | n/a | 2 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.48 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 4 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.78 | n/a | 3 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8114 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.32 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.19 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $54 → $41 | $21.39 | n/a | 2 | Aug 5, 2016 |
Eledon Pharmaceuticals
Jun 10, 2026
Reiterated: Buy
Price Target: $10
Current: $3.57
Upside: +180.11%
Greenwich LifeSciences
Jun 2, 2026
Reiterated: Buy
Price Target: $45
Current: $23.03
Upside: +95.40%
MAIA Biotechnology
Jun 2, 2026
Reiterated: Buy
Price Target: $14
Current: $1.30
Upside: +976.92%
GeoVax Labs
May 27, 2026
Reiterated: Buy
Price Target: $10
Current: $1.18
Upside: +747.46%
Cocrystal Pharma
May 27, 2026
Reiterated: Buy
Price Target: $6 → $10
Current: $1.01
Upside: +890.10%
Cardiff Oncology
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $1.59
Upside: +654.72%
Unicycive Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $60
Current: $7.69
Upside: +680.23%
Gyre Therapeutics
May 8, 2026
Reiterated: Buy
Price Target: $20
Current: $6.05
Upside: +230.58%
The Oncology Institute
May 8, 2026
Reiterated: Buy
Price Target: $8
Current: $5.13
Upside: +55.95%
Ocugen
May 6, 2026
Reiterated: Buy
Price Target: $12
Current: $1.22
Upside: +883.61%
May 1, 2026
Reiterated: Buy
Price Target: $45
Current: $4.03
Upside: +1,016.63%
Apr 6, 2026
Reiterated: Buy
Price Target: $15
Current: $3.52
Upside: +326.14%
Apr 1, 2026
Reiterated: Buy
Price Target: $9
Current: $0.739
Upside: +1,117.86%
Mar 16, 2026
Reiterated: Buy
Price Target: $70 → $37
Current: $10.65
Upside: +247.42%
Jun 27, 2025
Rated: Hold
Price Target: n/a
Current: $0.0983
Upside: -
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $1.27
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $1.12
Upside: n/a
Jan 21, 2025
Rated: Hold
Price Target: n/a
Current: $0.1749
Upside: n/a
Sep 24, 2024
Rated: Hold
Price Target: n/a
Current: $0.07
Upside: n/a
Aug 16, 2022
Reiterated: Buy
Price Target: $5
Current: $0.6536
Upside: n/a
Aug 15, 2022
Reiterated: Buy
Price Target: $8 → $9
Current: $1.28
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: $0.71
Current: $0.093
Upside: n/a
May 14, 2021
Maintained: Buy
Price Target: $20 → $20
Current: $2.50
Upside: n/a
Feb 9, 2021
Maintained: Buy
Price Target: $18 → $27
Current: $0.0001
Upside: n/a
Jan 26, 2021
Maintained: Buy
Price Target: $6 → $15
Current: $3.80
Upside: n/a
Jan 25, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $5.42
Upside: n/a
Jan 24, 2021
Maintained: Buy
Price Target: $6 → $14
Current: $1.25
Upside: n/a
Dec 28, 2020
Downgraded: Hold
Price Target: n/a
Current: $4.72
Upside: n/a
Dec 24, 2020
Maintained: Buy
Price Target: $6
Current: $1.10
Upside: n/a
Nov 12, 2020
Reiterated: Buy
Price Target: $8
Current: $0.0001
Upside: n/a
Oct 5, 2020
Downgraded: Hold
Price Target: n/a
Current: $11.05
Upside: n/a
May 28, 2020
Maintained: Buy
Price Target: $5
Current: $2.82
Upside: n/a
Feb 18, 2020
Initiated Coverage: Buy
Price Target: $30
Current: $2.01
Upside: n/a
Nov 1, 2018
Rated: Hold
Price Target: n/a
Current: $4.25
Upside: n/a
Nov 1, 2018
Rated: Hold
Price Target: n/a
Current: $3.57
Upside: n/a
Apr 10, 2018
Downgraded: Hold
Price Target: $17 → $1
Current: $31.74
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $3.48
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $7.78
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.8114
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $1.32
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $2.19
Upside: n/a
Aug 5, 2016
Downgraded: Hold
Price Target: $54 → $41
Current: $21.39
Upside: n/a